

QUARTERLY

PCPA UPDATE Q3 2022

July- September 2022

A high-level summary of the quarterly pan-Canadian Pharmaceutical Alliance (pCPA) activity & processes

pCPA ACTIVITY



Initiated 15 files
(Q2 2022: 11 files)



Completed 17 files
(Q2 2022: 14 files)




Closed 4 files
(Q2 2022: 7 file)



Declined 2 files
(Q2 2022: 3 files)


FILES UNDER CONSIDERATION



Insights

- CADTH issued 18 positive and 6 'Do Not Reimburse' recommendations in Q3 2022.
- Although pCPA initiated negotiations for 14 files during the quarter, the volume of files under consideration increased to a high of 47 as of September 30th.
- The average days under consideration decreased from 205 days in July to 180 days in September as the volume of newly under consideration files increased.
- The quarterly average days under consideration was 193 days, slightly less than last quarter (195 days) but above the annual average (185 days).

FILES UNDER NEGOTIATION




Insights


- pCPA initiated fewer files (15) than completed (17) and closed (4) in Q3, resulting in a net decrease in active negotiations.
- The average time under negotiation increased this quarter, reaching a high of 175 days in September. The quarterly average of 170 days again surpassed the annual average timelines (148 days).
- Two negotiations were initiated and completed on the same day: Inqovi and Trikafta.

pCPA CAPACITY

Volume of Processed Files



Long Term Files



Insights

- pCPA completed 17 negotiations with LOIs in Q3 2022, 3 more than Q2 2022 (14), but fewer than Q1 2022 (22).
- 4 files closed without reaching an agreement, comprised of 2 non-oncology files and 2 oncology files.
- 2 files were not negotiated, both of which were oncology files with negative recommendations from CADTH and INESSS.
- The number of files under consideration for >6 months increased to 13, 10 of which have negative recommendations from CADTH. The number of files under active negotiation for >12 months decreased to 2.